Molecular assessment of minimal residual disease in PBSC harvests provides prognostic information in neuroblastoma

被引：12
|
作者：
Chambon, F. [1 ,2 ,3 ]
Tchirkov, A. [3 ,4 ,5 ,6 ]
Pereira, B. [7 ]
Rochette, E. [1 ,2 ]
Demeocq, F. [1 ,2 ,3 ]
Kanold, J. [1 ,2 ,3 ]
机构：
[1] CHU Clermont Ferrand, Ctr Reg Cancerol & Therapie Cellulaire Pediat, Hop Estaing, Clermont Ferrand, France
[2] INSERM CIC 501, Clermont Ferrand, France
[3] Univ Clermont1, Fac Med, Clermont Univ, Clermont Ferrand, France
[4] CHU, EA ERTICa 4677, F-63003 Clermont Ferrand, France
[5] Ctr Lutte Canc Jean Perrin, Clermont Ferrand, France
[6] CHU Clermont Ferrand, Serv Cytogenet Med, Hop Estaing, Clermont Ferrand, France
[7] CHU Clermont Ferrand, Unite Biostat Delegat Rech Clin & Innovat, Clermont Ferrand, France
来源：
PEDIATRIC BLOOD & CANCER | 2013年 / 60卷 / 09期
关键词：
minimal residual disease; neuroblastoma; peripheral blood stem cells; RQ-PCR for tyrosine hydroxylase mRNA; STEM-CELL TRANSPLANTATION; HIGH-RISK NEUROBLASTOMA; BONE-MARROW; CONTAMINATION; CHILDREN; GRAFTS;
D O I：
10.1002/pbc.24538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
As almost all patients with high-risk neuroblastomas have autograft, we aimed to determine if minimal residual disease (MRD) quantified by RT-PCR for tyrosine hydroxylase in PBSC is prognostic in neuroblastomas. PBSC harvests from 38 children were analyzed. Seven had harvests positive for TH-mRNA. Patients with a positive MRD had a lower 2-year-overall-survival compared to those with negative MRD (P=0.04) regardless of whether or not PBSC were re-infused. Patients in CR/VGPR group with positive MRD have hazard ratio of death at 7.3 [1.3-40.5]. In conclusion, molecular MRD status in PBSC of good response group may be of interest as a survival prognostic factor in high-risk neuroblastomas. Pediatr Blood Cancer 2013;160:E109-E112. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码：E109 / E112
页数：4
相关论文
共 50 条
  • [1] Minimal Residual Disease is a Prognostic Marker for Neuroblastoma With Bone Marrow Infiltration
    Cai, Jiao-Yang
    Pan, Ci
    Tang, Yan-Jing
    Chen, Jing
    Ye, Qi-Dong
    Zhou, Min
    Xue, Huiliang
    Tang, Jing-Yan
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (03): : 275 - 278
  • [2] Prognostic impact and detection of minimal residual disease (MRD) in neuroblastoma patients
    Druy, Alexander
    Tsaur, Grigory
    Popov, Alexander
    Verzhbitskaya, Tatiana
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma
    Tchirkov, A
    Paillard, C
    Halle, P
    Bernard, F
    Bordigoni, P
    Vago, P
    Deméocq, F
    Kanold, J
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2003, 12 (04): : 435 - 442
  • [4] Minimal residual disease is detectable in peripheral blood of patients with acute myeloid leukemia and provides prognostic information
    Maurillo, L.
    Buccisano, F.
    Del Poeta, G.
    Spagnoli, A.
    Neri, B.
    Del Principe, M., I
    Ammatuna, E.
    Tendas, A.
    Luciano, F.
    De Fabritiis, P.
    Amadori, S.
    Vendetti, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 65 - 66
  • [5] Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information
    Minetto, Paola
    Guolo, Fabio
    Clavio, Marino
    Kunkl, Annalisa
    Colombo, Nicoletta
    Carminati, Enrico
    Fugazza, Giuseppina
    Matarese, Simona
    Guardo, Daniela
    Ballerini, Filippo
    Di Grazia, Carmen
    Raiola, Anna M.
    Cagnetta, Antonia
    Cea, Michele
    Miglino, Maurizio
    Lemoli, Roberto M.
    Gobbi, Marco
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (03) : 457 - 460
  • [6] Prognostic stratification and minimal residual disease assessment in Acute Myeloid Leukemia by molecular techniques
    Kakkas, I.
    ARCHIVES OF HELLENIC MEDICINE, 2013, 30 (05): : 566 - 573
  • [7] Persistent Bone Marrow Minimal Residual Disease is a Poor Prognostic Marker for Neuroblastoma
    Feng, C.
    Li, Y.
    Wu, P.
    Xiong, X.
    Peng, X.
    Weng, W.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S605 - S606
  • [8] Minimal Residual Disease in Peripheral Blood Stem Cell Harvests From High-risk Neuroblastoma Patients
    Avigard, Smadar
    Feinberg-Gorenshtein, Galina
    Luria, Dorit
    Jeison, Marta
    Stein, Jerry
    Grunshpan, Anna
    Sverdlov, Yacov
    Ash, Shifra
    Yaniv, Issac
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2009, 31 (01) : 22 - 26
  • [9] Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information
    Minetto, Paola
    Guolo, Fabio
    Clavio, Marino
    Kunkl, Annalisa
    Colombo, Nicoletta
    Carminati, Enrico
    Fugazza, Giuseppina
    Matarese, Simona
    Guardo, Daniela
    Ballerini, Filippo
    Di Grazia, Carmen
    Raiola, Anna Maria
    Cagnetta, Antonia
    Cea, Michele
    Miglino, Maurizio
    Lemoli, Roberto Massimo
    Gobbi, Marco
    BLOOD, 2017, 130
  • [10] MOLECULAR DETERMINATION OF MINIMAL RESIDUAL DISEASE IN PERIPHERAL-BLOOD STEM-CELL HARVESTS
    LANGLANDS, K
    CRAIG, JIO
    PARKER, AC
    ANTHONY, RS
    BONE MARROW TRANSPLANTATION, 1990, 5 : 64 - 65
12345